Senescent cells in melanoma tumors create a paradoxical double-edged sword: they suppress tumor growth through cell cycle arrest and immune activation, yet simultaneously promote immune evasion, metastasis, and therapy resistance via senescence-associated secretory phenotype (SASP) pathways. Preclinical models demonstrate that senolytic agents—drugs that selectively eliminate senescent cells—show enhanced efficacy when combined with immune checkpoint inhibitors, potentially eliminating therapy-induced senescent cells while boosting anti-tumor immunity. This mechanistic insight represents a significant advancement in understanding how aging biology intersects with cancer progression. The therapeutic implications extend beyond melanoma, as cellular senescence accumulates throughout the body with age and contributes to multiple age-related diseases. However, clinical translation faces substantial hurdles including the marked heterogeneity of senescent cell populations and context-dependent SASP effects that can be either beneficial or harmful. The field lacks robust melanoma-specific clinical data, making biomarker-driven patient selection crucial. This represents an incremental but important step toward precision oncology approaches that could simultaneously target cancer and underlying aging processes.